[Antitumor activity of Ca-double-stranded RNA from sodium nucleinate].
Ca-dsRNA introduced in the concentration of 5 micrograms per mouse 24 hours before the MG22a mouse hepatoma transplantation causes the 70% inhibition of the hepatoma growth. The sodium nucleinate used in the considerably higher concentration had a less effect. The sodium form of dsRNA also had a less antitumour effect comparing with its calcium form. The calcium form of dsRNA proves to be relatively stable and physiologically active form of dsRNA during its parenteral administration.
D000818:Animals; D002118:Calcium / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009696:Nucleic Acids / Q000627:therapeutic use*; D012330:RNA, Double-Stranded / Q000627:therapeutic use*; D012331:RNA, Fungal / Q000627:therapeutic use*
D009696:Nucleic Acids; D012330:RNA, Double-Stranded; D012331:RNA, Fungal; C013683:sodium nucleinate; D002118:Calcium
Protivoopukholevaia aktivnost' Ca-dvukhspiral'noĭ RNK iz nukleinata natriia.